Pharmacovigilance: a scientific system to ensure drug safety

Pharmacovigilance (PV) is a scientific system for monitoring, evaluating and preventing adverse drug reactions and other drug risks, which runs through the entire life cycle of drugs. Its core content includesAdverse reaction monitoring, risk signal identification, risk assessment and control, and promote rational drug use. In terms of primary and secondary structure, pharmacovigilance takes patient safety as the core and covers the three major links of drug research and development, post-marketing surveillance, and public education. It also relies on regulatory frameworks and technical means (such as big data analysis) to achieve dynamic risk management.

The core tasks and significance of pharmacovigilance

The first priority of pharmacovigilance isIdentify unknown risks. Even if a drug undergoes rigorous clinical trials with a limited subject population, rare or long-term adverse effects may manifest after marketing. For example, in 2004, rofecoxib (Vioxx) was recalled globally due to cardiovascular risks, which was discovered through post-marketing surveillance. In addition, pharmacovigilance also focuses onMedication errors, circulation of counterfeit and substandard drugsand other issues, by establishing a global database (such as WHO's VigiBase) to share risk information and improve early warning efficiency. Its significance is not only to reduce patient harm, but also to optimize drug instructions and guide clinical decision-making.

Implementation process and technical means of pharmacovigilance

Pharmacovigilance passedActive monitoring combined with passive reportingCarry out work. Passive reporting relies on medical institutions, pharmaceutical companies and patients to submit adverse reaction cases; active monitoring uses electronic health records, medical insurance data, etc. to conduct real-world research. For example, the FDA's Sentinel system can analyze hundreds of millions of data in real time and quickly identify risk signals. In recent years, artificial intelligence-assisted natural language processing (NLP) technology has been used to mine medication feedback in social media and supplement traditional monitoring blind spots. However, technology needs to be combined with expert assessment to avoid misjudgment.

Regulatory framework and global collaboration

Countries have established pharmacovigilance regulatory systems, such as China’s Adverse Drug Reaction Reporting and Monitoring Management Measures and the EU’s EudraVigilance system. International organizations (WHO, ICH) coordinate standards and promote data interoperability. Pharmaceutical companies are the main body of responsibility and need to set up dedicated departments. For example, multinational pharmaceutical companies such as Pfizer and Novartis are equipped with global PV teams. Chinese pharmaceutical companies such as Hengrui Pharmaceuticals and CSPC Pharmaceutical Group have also gradually improved their monitoring systems. Regulations require companies to regularly submitPeriodic Security Update Report (PSUR), major risks require emergency notification.

Summary: The future of pharmacovigilance and public engagement

The future of pharmacovigilance will rely even more onReal World Evidence (RWE) and intelligent tools, but lack of public awareness remains a challenge. According to statistics, China will have only 1,764 reported cases of adverse reactions per million people in 2022, which is lower than developed countries. It is necessary to strengthen public education and encourage patients to report problems through channels such as the "Adverse Drug Reaction Monitoring APP". Only through multi-party collaboration among pharmaceutical companies, regulatory agencies, medical staff and patients can we build a safer medication environment.

Quote sources:
1. WHO International Drug Monitoring Project (VigiBase)
2. China's "Adverse Drug Reaction Reporting and Monitoring Management Measures" (State Food and Drug Administration 2022 revised version)
3. FDA drug alert south (2021)
4. Case data reference:"Drug Safety and Risk Management"(Zhang Liang, People's Medical Publishing House)